Toronto, Canada - June 5, 2008 - For Immediate Release
Medical device manufacturers are seeking alternatives to contaminated heparin coatings used to prevent thrombus in medical devices.
Recent studies performed on catheters treated with Interface Biologics' s EndexoTM additive showed a 98% reduction in thrombus accumulation versus a control in blood loop studies.
"The difference between the EndexoTM additive and the control was significant in an in-vitro flow model using bovine blood" stated Sivaprasad Sukavaneshvar, Ph.D., Vice President of the Medical Device Evaluation Center (MDEC)in Salt Lake City, Utah.
In addition, In vivo sheep studies performed at MDEC yielded a 20% reduction in occlusive days under aspiration and a 50% reduction in occlusive days under infusion versus the control.
For more information go to http://files.newswire.ca/722/Endexo-Studies.pdf